New cell therapy takes on Drug-Resistant melanoma
Disease control
Not yet recruiting
This phase 2 trial tests a new cell therapy called RAPA-201 for people with advanced melanoma that has spread or come back after standard immunotherapy. The treatment uses a patient's own immune cells that are specially trained to resist a drug called rapamycin, aiming to boost t…
Phase: PHASE2 • Sponsor: Rapa Therapeutics LLC • Aim: Disease control
Last updated May 03, 2026 10:06 UTC